Skip to main content

Table 3 Tumor characteristics for all young breast cancer patients according to the time of diagnosis (n = 1099)

From: Loco-regional recurrence trend and prognosis in young women with breast cancer according to molecular subtypes: analysis of 1099 cases

 

2006

2007

2008

2009

2010

2011

2012

2013

2014

P

n = 55

n = 73

n = 96

n = 93

n = 132

n = 154

n = 147

n = 166

n = 183

Tumor size

 T1

21 (38)

27 (37)

39 (41)

37 (40)

45 (34)

64 (42)

49 (33)

62 (37)

76 (42)

0.539

 T2

30 (55)

34 (47)

43 (45)

42 (45)

61 (46)

65 (42)

75 (51)

82 (49)

76 (42)

 

 T3

2 (4)

3 (4)

5 (5)

5 (5)

16 (12)

13 (8)

15 (10)

12 (7)

17 (9)

 

 T4

1 (2)

2 (3)

3 (3)

0 (0)

1 (1)

1 (1)

4 (3)

2 (1)

2 (1)

 

 Tx

1 (2)

7 (10)

6 (6)

9 (10)

9 (7)

11 (7)

4 (3)

8 (5)

12 (7)

 

Stage

         

0.004

 I

11 (20)

21 (29)

27 (28)

24 (26)

30 (23)

40 (26)

35 (24)

45 (27)

49 (27)

 

 II a

24 (44)

20 (27)

37 (39)

36 (39)

41 (31)

47 (31)

56 (38)

51 (31)

71 (39)

 

 II b

4 (7)

11 (15)

9 (9)

13 (14)

17 (13)

19 (12)

27 (18)

36 (22)

23 (13)

 

 III a

13 (23)

7 (10)

8 (8)

8 (9)

22 (17)

20 (13)

13 (9)

14 (8)

21 (12)

 

 III b

0 (0)

2 (3)

0 (0)

0 (0)

0 (0)

0 (0)

2 (1)

2 (1)

2 (1)

 

 III c

3 (6)

5 (7)

14 (15)

4 (4)

14 (11)

21 (14)

12 (8)

13 (8)

11 (6)

 

 Unknown

0 (0)

7 (10)

1 (1)

8 (9)

8 (6)

7 (5)

2 (1)

5 (3)

6 (3)

 

LNM

         

0.007

 N0

30 (55)

42 (58)

56 (58)

52 (56)

67 (51)

73 (47)

80 (54)

83 (50)

102 (56)

 

 N1

8 (15)

15 (21)

19 (20)

26 (28)

30 (23)

38 (25)

41 (28)

54 (33)

45 (25)

 

 N2

13 (24)

11 (15)

6 (6)

10 (11)

19 (14)

20 (13)

12 (8)

15 (9)

18 (10)

 

 N3

4 (7)

5 (7)

14 (15)

5 (5)

14 (11)

21 (14)

11 (8)

11 (7)

9 (5)

 

 Unknown

0 (0)

0 (0)

1 (1)

0 (0)

2 (2)

2 (1)

3 (2)

3 (2)

9 (4.9)

 

HG

         

0.415

 Well

4 (7)

2 (3)

6 (6)

3 (3)

4 (3)

8 (5)

3 (2)

3 (2)

2 (1)

 

 Moderately

32 (58)

35 (48)

47 (49)

53 (57)

76 (58)

84 (55)

86 (59)

87 (52)

94 (51)

 

 Poorly

6 (11)

10 (14)

11 (12)

10 (11)

16 (12)

26 (17)

23 (16)

29 (18)

32 (18)

 

 Unknown

13 (24)

26 (36)

32 (33)

27 (30)

36 (27)

36 (23)

35 (24)

47 (28)

55 (30)

 

PT

         

0.620

 IDC

48 (87)

68 (93)

80 (83)

86 (93)

119 (90)

140 (90)

136 (93)

153 (92)

169 (92)

 

 ILC

0 (0)

1 (1)

1 (1)

1 (1)

2 (2)

2 (1)

0 (0)

1 (1)

2 (1)

 

 Others

7 (13)

4 (6)

15 (16)

6 (7)

12 (8)

12 (8)

11 (8)

12 (7)

12 (7)

 

MS

         

0.043

 HR+/HER2−

32 (58)

49 (67)

51 (53)

50 (54)

68 (52)

90 (58)

72 (49)

89 (54)

93 (51)

 

 HR+/HER2+

9 (16)

9 (12)

7 (7)

5 (5)

9 (7)

21 (14)

15 (10)

22 (13)

23 (13)

 

 HR−/HER2+

3 (6)

6 (8)

6 (6)

5 (5)

12 (9)

13 (8)

12 (8)

11 (7)

7 (4)

 

 HR−/HER2−

8 (15)

6 (8)

20 (21)

26 (28)

33 (25)

16 (10)

28 (19)

27 (16)

37 (20)

 

 Unknown

3 (6)

3 (4)

12 (13)

7 (8)

10 (8)

14 (9)

20 (14)

17 (10.2)

23 (13)

 

Final surgery

         

0.792

 BCS

15 (27)

22 (30)

23 (24)

17 (18)

30 (23)

32 (21)

34 (23)

42 (25)

42 (23)

 

 Mastectomy

40 (72)

51 (70)

73 (76)

76 (82)

102 (77)

122 (79)

113 (77)

124 (75)

141 (77)

 
  1. All data are given as no. of patients (%). Percentages may not add up to 100% as a result of rounding
  2. LNM, lymph node metastasis; HG, histological grade; PT, pathological type; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; NACT, neoadjuvant chemotherapy; MS, molecular subtype; BCS, breast conserving surgery